BC-006

Main purpose Dose escalation phase: To evaluate the safety and tolerability of BC006 monoclonal antibody injection in the treatment of patients with advanced solid tumors including tenosynovial giant cell tumors, explore the maximum tolerated dose (MTD), and determine the recommended dose (RP2D) for clinical trials. Dose expansion phase: To explore the safety and tolerability of BC006 monoclonal antibody injection in the treatment of patients with advanced solid tumors including tenosynovial giant cell tumors. To evaluate the objective response rate (ORR) of subjects with different tumor types. Secondary objectives (1) To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of BC006 monoclonal antibody injection. (2) To evaluate the immunogenicity characteristics. (3) To analyze the disease control rate (DCR), progression-free survival (PFS) of the subjects, and to evaluate the effectiveness of BC006 monoclonal antibody injection in different tumor types.